Skip to content
Screener

Metagenomi Therapeutics, Inc. MGX Q3 2025 earnings

Reported November 11, 2025 · Before market open

Revenue$8.7MBeat by $836.4K
EPS-$0.55Beat by $0.05
Revenue estimate$7.8M
EPS estimate-$0.60

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$2.6M
EPS estimate-$0.64

FAQ

When did Metagenomi Therapeutics, Inc. report Q3 2025 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q3 2025 earnings on November 11, 2025 before market open.
What were Metagenomi Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $8.7M and eps of $-0.55 for Q3 2025.
Did Metagenomi Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $7.8M by $836.4K. EPS beat the consensus estimate of $-0.60 by $0.05.
How did Metagenomi Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 24.8% from $11.5M a year earlier and eps declined 22.2% from $-0.45.
Where can I find Metagenomi Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-276135) and the 10-Q periodic report (0001193125-25-276150) directly on SEC EDGAR. The filing index links above go to sec.gov.